Tuesday, September 29, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Marketsgrey wolf healthcompounding pharmacytsxv

Grey Wolf Health drops 'Animal' from name to target human compounding

The TSX Venture-listed company is repositioning from veterinary roots toward the human compounding pharmacy market.

TR
By Tom Reyes · Markets Editor
Sep 28 13:19 ETSource: kalkine.ca

The wire

  1. 01Grey Wolf Health (TSXV:WOLF) changed its corporate name, removing 'Animal,' as part of a shift toward growth in human compounding pharmacy.
  2. 02Compounding capacity and ownership changes matter to prescribers and telehealth operators tracking where compounded preparations are sourced.
  3. 03Details of licensing, facility status and 503A or 503B registration were not set out; the rebrand alone does not establish human compounding operations.

From the source

Why Grey Wolf Health (TSXV:WOLF) Dropped 'Animal' From Its Name to Chase Human Compounding Pharmacy Growth

Read at kalkine.ca
PeptiPrescribed peptides from $99/moSee all →